Q2 2026 saw 20%+ revenue growth, record profitability, and margin expansion, driven by strong demand and operational discipline. The VitalConnect acquisition will expand cardiac monitoring capabilities and address new market segments, with integration expected to accelerate growth from 2027.Based o…
Medical technology company iRhythm Technologies NASDAQ:IRTCbeat Wall Street’s revenue expectations in Q2 CY2026, with sales up 20.1% year on year to $224.2 million. The company expects the full year’s revenue to be around $885 million, close to analysts’ estimates. Its non-GAAP profit of $0.58 per…
Q2 2026 revenue grew 20.1% year-over-year to $224.2 million, with gross margin up to 72.8% and adjusted EBITDA margin at 19.3%. Updated 2026 guidance reflects slightly lower revenue and margin targets, while international expansion and new AI-driven products support future growth.Original document…
Medical technology company iRhythm Technologies NASDAQ:IRTCwill be reporting results this Thursday after market hours. Here’s what to look for.iRhythm beat analysts’ revenue expectations last quarter, reporting revenues of $199.4 million, up 25.7% year on year. It was a very strong quarter for the…
SAN FRANCISCO, July 16, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. NASDAQ:IRTC, a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will release financial results for the second quarter 2026 after the cl…
